KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Moderna (MRNA) over the last 6 years, with Q3 2025 value amounting to $207.0 million.

  • Moderna's Cost of Revenue fell 5972.76% to $207.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 3016.93%. This contributed to the annual value of $1.5 billion for FY2024, which is 6880.46% down from last year.
  • Latest data reveals that Moderna reported Cost of Revenue of $207.0 million as of Q3 2025, which was down 5972.76% from $119.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Cost of Revenue registered a high of $2.2 billion during Q3 2023, and its lowest value of $90.0 million during Q1 2025.
  • Moreover, its 5-year median value for Cost of Revenue was $739.0 million (2024), whereas its average is $768.7 million.
  • Per our database at Business Quant, Moderna's Cost of Revenue soared by 1180000.0% in 2021 and then plummeted by 8787.88% in 2024.
  • Quarter analysis of 5 years shows Moderna's Cost of Revenue stood at $952.0 million in 2021, then surged by 101.47% to $1.9 billion in 2022, then crashed by 51.56% to $929.0 million in 2023, then dropped by 20.45% to $739.0 million in 2024, then plummeted by 71.99% to $207.0 million in 2025.
  • Its Cost of Revenue was $207.0 million in Q3 2025, compared to $119.0 million in Q2 2025 and $90.0 million in Q1 2025.